What the business is, and whether it's a good one at a fair price.
Manufactures ayurvedic and nutraceutical products from a facility at Xcelon Industrial Park in Ahmedabad, Gujarat, and also offers CDMO (contract development and manufacturing) services to other companies. FY26 revenue was Rs. 33.60 crore, up 110% from Rs. 16.00 crore in FY25, with growth driven by demand for its nutraceutical and ayurvedic products, an expanded customer base, a richer product mix and higher CDMO contribution. Profit after tax was Rs. 5.07 crore on EBITDA of Rs. 7.01 crore. The business runs on a very raw-material-heavy cost structure: materials accounted for 73.6% of FY26 revenue, against just 3.2% for employees and 4.6% for other operating expenses. It follows an export-led strategy, winning a Global Export Excellence Award in Ayurvedic and Nutraceutical Manufacturing, and is working on product registrations and market approvals in international markets. The company raised Rs. 24.77 crore through an IPO and listed on the BSE SME platform in February 2026, using Rs. 7.04 crore of the proceeds on machinery, Rs. 5.24 crore on working capital, Rs. 3.69 crore on corporate purposes and Rs. 3.33 crore on IPO expenses, with Rs. 6.55 crore still unutilised.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from Accretion Nutraveda Limited's filed financials and exchange disclosures
Accretion Nutraveda Limited is a Pharmaceuticals & Biotechnology company listed on BSE.
Effectively yes. It holds ₹1 Cr more cash than debt.
On trailing P/E, Accretion Nutraveda Limited ranks 138 of 169 in Pharmaceuticals — cheaper than 19% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session Accretion Nutraveda Limited moves 2.66% — that is the median absolute close-to-close move across its last 117 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by Accretion Nutraveda Limited appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
